CSS LLC’s Ligand Pharmaceuticals LGND Stock Holding History

CSS LLC’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,810	Closed	-$203K	–	885
2023 Q2	$203K	Hold	2,810	–	–	0.01%	648
2023 Q1	$207K	Buy	+2,810	New	+$200K	0.01%	521

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS LLC's LGND Position: Q3 2023 in Review

CSS LLC sold out of Ligand Pharmaceuticals (LGND) in Q3 2023, closing a stake of 2,810 shares — an estimated $203K sold.

CSS LLC first reported a position in LGND in Q1 2023 and held it in 2 quarters. The position peaked at $207K in Q1 2023. 196 funds tracked by Wall St. Rank hold LGND as of Q3 2023.

CSS LLC reported no remaining Ligand Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
CSS LLC sold 2,810 Ligand Pharmaceuticals shares in Q3 2023, an estimated $203K.
CSS LLC first reported a position in Ligand Pharmaceuticals in Q1 2023 and held it in 2 quarters.
CSS LLC's Ligand Pharmaceuticals position peaked at $207K in Q1 2023.
196 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2023.

Based on CSS LLC's 13F filing for Q3 2023, filed 14 Nov 2023.